Switch to:
Also traded in: Australia, Germany, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt No Debt
PSDV's Cash-to-Debt is ranked higher than
99% of the 733 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.95 vs. PSDV: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
PSDV' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.47  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.75
PSDV's Equity-to-Asset is ranked higher than
72% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. PSDV: 0.75 )
Ranked among companies with meaningful Equity-to-Asset only.
PSDV' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.47  Med: 0.7 Max: 0.91
Current: 0.75
0.47
0.91
Interest Coverage No Debt
PSDV's Interest Coverage is ranked higher than
99% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 88.12 vs. PSDV: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PSDV' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: -16.11
Beneish M-Score: -0.42
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -273.88
PSDV's Operating Margin % is ranked lower than
91% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.19 vs. PSDV: -273.88 )
Ranked among companies with meaningful Operating Margin % only.
PSDV' s Operating Margin % Range Over the Past 10 Years
Min: -2445.54  Med: -474.92 Max: 39.44
Current: -273.88
-2445.54
39.44
Net Margin % -271.34
PSDV's Net Margin % is ranked lower than
91% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. PSDV: -271.34 )
Ranked among companies with meaningful Net Margin % only.
PSDV' s Net Margin % Range Over the Past 10 Years
Min: -4638.7  Med: -469.92 Max: 37.97
Current: -271.34
-4638.7
37.97
ROE % -102.43
PSDV's ROE % is ranked lower than
92% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. PSDV: -102.43 )
Ranked among companies with meaningful ROE % only.
PSDV' s ROE % Range Over the Past 10 Years
Min: -133.19  Med: -97.19 Max: 33.15
Current: -102.43
-133.19
33.15
ROA % -68.38
PSDV's ROA % is ranked lower than
92% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. PSDV: -68.38 )
Ranked among companies with meaningful ROA % only.
PSDV' s ROA % Range Over the Past 10 Years
Min: -95.61  Med: -65.97 Max: 23.06
Current: -68.38
-95.61
23.06
ROC (Joel Greenblatt) % -6725.71
PSDV's ROC (Joel Greenblatt) % is ranked lower than
96% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.39 vs. PSDV: -6725.71 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PSDV' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -15359.59  Med: -6301.23 Max: 16680.73
Current: -6725.71
-15359.59
16680.73
3-Year Revenue Growth Rate -18.10
PSDV's 3-Year Revenue Growth Rate is ranked lower than
90% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. PSDV: -18.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PSDV' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 16.8 Max: 365.7
Current: -18.1
0
365.7
3-Year EBITDA Growth Rate 11.30
PSDV's 3-Year EBITDA Growth Rate is ranked higher than
52% of the 577 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.20 vs. PSDV: 11.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PSDV' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 10.8 Max: 933.8
Current: 11.3
0
933.8
3-Year EPS without NRI Growth Rate 9.40
PSDV's 3-Year EPS without NRI Growth Rate is ranked higher than
53% of the 548 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. PSDV: 9.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PSDV' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 16.05 Max: 348.3
Current: 9.4
0
348.3
GuruFocus has detected 3 Warning Signs with pSivida Corp $PSDV.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PSDV's 10-Y Financials

Financials (Next Earnings Date: 2017-05-07 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

PSDV Guru Trades in Q1 2016

Ken Fisher 12,057 sh (unchged)
Jim Simons 574,800 sh (-3.52%)
» More
Q2 2016

PSDV Guru Trades in Q2 2016

Jim Simons 586,900 sh (+2.11%)
Ken Fisher 12,057 sh (unchged)
» More
Q3 2016

PSDV Guru Trades in Q3 2016

Jim Simons 677,100 sh (+15.37%)
Ken Fisher 12,057 sh (unchged)
» More
Q4 2016

PSDV Guru Trades in Q4 2016

Jim Simons 907,000 sh (+33.95%)
Ken Fisher 12,057 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with PSDV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 334516    SIC: 3826
Compare:NYSE:VRX » details
Traded in other countries:PVA.Australia, PV3.Germany, PSIZF.USA,
pSivida Corp develops tiny, sustained-release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years.

pSivida Corp was organized as a Delaware Corporation in March 2008. The Company develops tiny, sustained-release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. It is engaged in the treatment of chronic diseases of the back of the eye utilizing its core technology platforms, Durasert and BioSilicon. It currently has three approved products, as well as two current product candidates in clinical trials and uses different generations of this technology system. It has developed three of the four sustained release devices for treatment of retinal diseases currently approved in the U.S. or the European Union (EU). ILUVIEN, its recently approved product, is an injectable, sustained-release micro-insert that provides treatment of vision impairment associated with chronic diabetic macular edema considered insufficiently responsive to available therapies over a period of up to three years. ILUVIEN is being developed by its licensee Alimera Sciences, Inc. (Alimera). ILUVIEN has received marketing authorization in the United Kingdom, Austria, France, Germany and Portugal and marketing authorization is pending in Italy and Spain. Alimera is also seeking marketing approval for ILUVIEN for DME in the U.S. Alimera has announced its intention to launch in France in the first quarter of 2014. Its competitors and potential competitors are larger, established and more experienced and have more resources than the Company or its partners. Durasert, Medidur, Tethadur and BioSilicon are its trademarks.

Ratios

vs
industry
vs
history
PB Ratio 4.32
PSDV's PB Ratio is ranked lower than
66% of the 898 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. PSDV: 4.32 )
Ranked among companies with meaningful PB Ratio only.
PSDV' s PB Ratio Range Over the Past 10 Years
Min: 0.01  Med: 2.88 Max: 11.73
Current: 4.32
0.01
11.73
PS Ratio 9.21
PSDV's PS Ratio is ranked lower than
80% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. PSDV: 9.21 )
Ranked among companies with meaningful PS Ratio only.
PSDV' s PS Ratio Range Over the Past 10 Years
Min: 0.38  Med: 8.93 Max: 123.95
Current: 9.21
0.38
123.95
EV-to-EBIT -2.46
PSDV's EV-to-EBIT is ranked lower than
99.99% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.12 vs. PSDV: -2.46 )
Ranked among companies with meaningful EV-to-EBIT only.
PSDV' s EV-to-EBIT Range Over the Past 10 Years
Min: -478.6  Med: -3.1 Max: 613.2
Current: -2.46
-478.6
613.2
EV-to-EBITDA -2.59
PSDV's EV-to-EBITDA is ranked lower than
99.99% of the 783 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.99 vs. PSDV: -2.59 )
Ranked among companies with meaningful EV-to-EBITDA only.
PSDV' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1805.2  Med: -2.3 Max: 63.5
Current: -2.59
-1805.2
63.5
Current Ratio 3.76
PSDV's Current Ratio is ranked higher than
68% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.38 vs. PSDV: 3.76 )
Ranked among companies with meaningful Current Ratio only.
PSDV' s Current Ratio Range Over the Past 10 Years
Min: 0.26  Med: 5.61 Max: 17.6
Current: 3.76
0.26
17.6
Quick Ratio 3.76
PSDV's Quick Ratio is ranked higher than
75% of the 628 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. PSDV: 3.76 )
Ranked among companies with meaningful Quick Ratio only.
PSDV' s Quick Ratio Range Over the Past 10 Years
Min: 0.26  Med: 5.61 Max: 17.6
Current: 3.76
0.26
17.6
Days Sales Outstanding 24.26
PSDV's Days Sales Outstanding is ranked higher than
89% of the 587 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.21 vs. PSDV: 24.26 )
Ranked among companies with meaningful Days Sales Outstanding only.
PSDV' s Days Sales Outstanding Range Over the Past 10 Years
Min: 8.55  Med: 81.04 Max: 493.85
Current: 24.26
8.55
493.85

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -13.60
PSDV's 3-Year Average Share Buyback Ratio is ranked lower than
76% of the 446 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.00 vs. PSDV: -13.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PSDV' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -467.6  Med: -7.9 Max: 0
Current: -13.6
-467.6
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 5.05
PSDV's Price-to-Net-Cash is ranked higher than
73% of the 268 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.85 vs. PSDV: 5.05 )
Ranked among companies with meaningful Price-to-Net-Cash only.
PSDV' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.45  Med: 6.67 Max: 223.64
Current: 5.05
0.45
223.64
Price-to-Net-Current-Asset-Value 4.68
PSDV's Price-to-Net-Current-Asset-Value is ranked higher than
72% of the 615 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.44 vs. PSDV: 4.68 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PSDV' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.16  Med: 5.66 Max: 94.62
Current: 4.68
0.16
94.62
Price-to-Tangible-Book 4.56
PSDV's Price-to-Tangible-Book is ranked lower than
55% of the 830 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.52 vs. PSDV: 4.56 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PSDV' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.15  Med: 5.59 Max: 33.47
Current: 4.56
0.15
33.47
Price-to-Median-PS-Value 1.03
PSDV's Price-to-Median-PS-Value is ranked higher than
70% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.18 vs. PSDV: 1.03 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PSDV' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.09  Med: 1.53 Max: 906.67
Current: 1.03
0.09
906.67
Earnings Yield (Greenblatt) % -40.62
PSDV's Earnings Yield (Greenblatt) % is ranked lower than
95% of the 1021 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.62 vs. PSDV: -40.62 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PSDV' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -46.04  Med: 7.3 Max: 20.6
Current: -40.62
-46.04
20.6

More Statistics

Revenue (TTM) (Mil) $6.88
EPS (TTM) $ -0.73
Beta1.88
Short Percentage of Float0.71%
52-Week Range $1.50 - 4.25
Shares Outstanding (Mil)34.18
» More Articles for PSDV

Headlines

Articles On GuruFocus.com
Weekly CEO Sales Highlight: pSivida Corp., Equity Residential, Ciena Corp., Sabre Corp. Dec 28 2015 
pSivida Ltd. Reports Operating Results (10-Q) Feb 10 2011 
pSivida Ltd. Reports Operating Results (10-Q) Nov 09 2010 
pSivida Ltd. Reports Operating Results (10-K) Sep 27 2010 
pSivida Ltd. Reports Operating Results (10-Q) May 13 2010 
pSivida Ltd. Reports Operating Results (10-Q) Feb 12 2010 
pSivida Ltd. Reports Operating Results (10-Q) Nov 13 2009 
pSivida Ltd. Reports Operating Results (10-K) Sep 25 2009 
pSivida Ltd. Reports Operating Results (10-Q) May 13 2009 
pSivida Ltd. Reports Operating Results (10-Q) Feb 11 2009 

More From Other Websites
pSivida Corp. :PSDV-US: Earnings Analysis: Q2, 2017 By the Numbers : March 20, 2017 Mar 20 2017
Abstract on pSivida's Treatment of Posterior Segment Uveitis Accepted for Presentation at the 2017... Mar 15 2017
PSIVIDA CORP. Files SEC form 8-K, Other Events Mar 06 2017
PSIVIDA CORP. Financials Feb 15 2017
pSivida to Present at the 2017 BIO CEO & Investor Conference Feb 10 2017
PSIVIDA CORP. Files SEC form 10-Q, Quarterly Report Feb 09 2017
PSIVIDA CORP. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Feb 08 2017
Edited Transcript of PSDV earnings conference call or presentation 7-Feb-17 9:30pm GMT Feb 07 2017
PSivida posts 2Q loss Feb 07 2017
PSivida posts 2Q loss Feb 07 2017
PSIVIDA CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 07 2017
pSivida Corp. Reports Fiscal 2017 Second Quarter and First Half Results Feb 07 2017
Q2 2017 pSivida Corp Earnings Release - After Market Close Feb 07 2017
pSivida Corp. Announces Second Quarter Fiscal Year 2017 Financial Results Release Date and... Jan 25 2017
PSIVIDA CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Jan 10 2017
PSIVIDA CORP. Files SEC form 8-K, Termination of a Material Definitive Agreement, Change in... Dec 30 2016
PSIVIDA CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Dec 23 2016
PSIVIDA CORP. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 20 2016
pSivida Corp. (PSDV): Here’s How It Stacks Up Versus Its Peers Dec 16 2016
PSIVIDA CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters... Dec 16 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)